+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients

Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients

Przeglad Epidemiologiczny 57(2): 299-307

ISSN/ISBN: 0033-2100

PMID: 12910598

A steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients is considered as a major problem. However, there still remains much uncertainty regarding the best methods for establishing the diagnosis of most IFIs. An international consensus proposed three levels of probability in defining opportunistic IFIs: proven, probable, and possible. Practicing physicians approach this uncertainty by prophylaxis and antifungal empirical therapy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 003694585

Download citation: RISBibTeXText

Related references

Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?. Current Opinion in Infectious Diseases 15(4): 369-375, 2002

The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea. Annals of Hematology 93(1): 33-42, 2014

Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. Journal of Antimicrobial ChemoTherapy 41(3): 373-380, 1998

Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia. Annals of Hematology 95(6): 1001-1009, 2016

Pre-emptive versus empirical antifungal therapy in immunocompromised children. Lancet. Child and Adolescent Health 3(8): 518-520, 2019

Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 55(1): 2-16, 2012

Antifungal Prophylaxis in Immunocompromised Patients. Mediterranean Journal of Hematology and Infectious Diseases 8(1): E2016040, 2016

Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients. International Journal of Clinical and Experimental Medicine 8(7): 11794-11802, 2015

Should an antifungal prophylaxis be proposed to critically ill non immunocompromised patients?. Conference de consensus commune: Prise en charge des candidoses et aspergilloses invasives de l' adulte, Institut Pasteur de Paris, France, 13 mai 2004: 87-92, 2004

A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. Journal of Antimicrobial ChemoTherapy 70(4): 1166-1174, 2015

Systemic antifungal therapy in patients without documented invasive fungal infection: a peek into the world of empirical antifungal therapy*. Critical Care Medicine 40(3): 997-998, 2012

Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?. International Journal of Antimicrobial Agents 32 Suppl. 2: S149-S153, 2008

Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients. Minerva Pediatrica 62(1): 57-69, 2010

Antifungal therapy in immunocompromised patients. Deltion Ellenikes Mikrobiologikes Etaireias 36(6): 790-798, 1991

Cross-sectional investigation of first-choice of antifungal agents in empirical and preemptive antifungal therapy for patients with hematological malignancies. Zhonghua Xue Ye Xue Za Zhi 34(6): 473-477, 2013